Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
111Indium-bevacizumab
- Development stage
- Preclinical
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
111Indium-bevacizumab is a radiopharmaceutical consisting of bevacizumab labeled with the radioactive isotope Indium-111. Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that binds to vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis by preventing VEGF-A from binding to its receptors on endothelial cells. The radiolabeling with 111Indium allows for diagnostic imaging and tracking of the antibody distribution in the body, which can be useful for research and potentially for diagnostic applications in cancer patients.
- Other names
- 111In-labeled bevacizumabIndium (111In) bevacizumab111In-DOTA-bevacizumab
02
Targets
Beyond the preview
Go deeper on 111Indium-bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 111Indium-bevacizumab.